IL161744A0 - Combination therapy comprising zd6474 and a taxane - Google Patents

Combination therapy comprising zd6474 and a taxane

Info

Publication number
IL161744A0
IL161744A0 IL16174402A IL16174402A IL161744A0 IL 161744 A0 IL161744 A0 IL 161744A0 IL 16174402 A IL16174402 A IL 16174402A IL 16174402 A IL16174402 A IL 16174402A IL 161744 A0 IL161744 A0 IL 161744A0
Authority
IL
Israel
Prior art keywords
taxane
combination therapy
therapy
combination
Prior art date
Application number
IL16174402A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL161744A0 publication Critical patent/IL161744A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL16174402A 2001-11-08 2002-11-06 Combination therapy comprising zd6474 and a taxane IL161744A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0126879.6A GB0126879D0 (en) 2001-11-08 2001-11-08 Combination therapy
PCT/GB2002/005021 WO2003039551A1 (en) 2001-11-08 2002-11-06 Combination therapy comprising zd6474 and a taxane

Publications (1)

Publication Number Publication Date
IL161744A0 true IL161744A0 (en) 2005-11-20

Family

ID=9925430

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16174402A IL161744A0 (en) 2001-11-08 2002-11-06 Combination therapy comprising zd6474 and a taxane
IL161744A IL161744A (en) 2001-11-08 2004-05-03 Use of zd6474 and taxane in the manufacture of a medicament for the treatment of cancer and pharmaceutical compositions and kits comprising such compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL161744A IL161744A (en) 2001-11-08 2004-05-03 Use of zd6474 and taxane in the manufacture of a medicament for the treatment of cancer and pharmaceutical compositions and kits comprising such compounds

Country Status (22)

Country Link
US (2) US20050043395A1 (https=)
EP (1) EP1446124B1 (https=)
JP (1) JP4694127B2 (https=)
KR (1) KR100959607B1 (https=)
CN (1) CN1298328C (https=)
AR (1) AR037346A1 (https=)
AT (1) ATE335488T1 (https=)
AU (1) AU2002337382B2 (https=)
BR (1) BR0213906A (https=)
CA (1) CA2464758C (https=)
CY (1) CY1106259T1 (https=)
DE (1) DE60213845T2 (https=)
DK (1) DK1446124T3 (https=)
ES (1) ES2269769T3 (https=)
GB (1) GB0126879D0 (https=)
IL (2) IL161744A0 (https=)
MX (1) MXPA04004355A (https=)
NO (1) NO328048B1 (https=)
NZ (1) NZ532525A (https=)
PT (1) PT1446124E (https=)
WO (1) WO2003039551A1 (https=)
ZA (1) ZA200403455B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100881105B1 (ko) * 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ES2267748T3 (es) 2000-04-07 2007-03-16 Astrazeneca Ab Compuestos de quinazolina.
SI1474420T1 (sl) * 2002-02-01 2012-06-29 Astrazeneca Ab Spojine kinazolina
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
AU2003278383B2 (en) 2002-11-04 2007-06-14 Astrazeneca Ab Quinazoline derivatives as Src tyrosine kinase inhibitors
KR20050100683A (ko) * 2003-02-13 2005-10-19 아스트라제네카 아베 5-ｆｕ 또는/및 ｃｐｔ-11과 ｚｄ6474의 병용 요법
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
EP1648465B1 (en) * 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
WO2006002422A2 (en) * 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
PL1971338T3 (pl) * 2005-12-22 2011-07-29 Astrazeneca Ab Połączenie ZD6474 i premetreksedu
EP2094268A2 (en) * 2006-05-26 2009-09-02 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
JP5739802B2 (ja) 2008-05-13 2015-06-24 アストラゼネカ アクチボラグ ４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
WO2010061208A2 (en) * 2008-11-03 2010-06-03 Astrazeneca Ab Therapeutic treatment 555
CN106478598B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种凡德他尼水合物晶体及其制备方法
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法
JP7737455B2 (ja) * 2020-12-22 2025-09-10 ハンミ ファーマシューティカル カンパニー リミテッド Ｓｏｓ１阻害剤としての新規キナゾリン誘導体化合物及びその用途｛ｎｏｖｅｌ ｑｕｉｎａｚｏｌｉｎｅ ｄｅｒｉｖａｔｉｖｅｓ ａｓ ｓｏｓ１ ｉｎｈｉｂｉｔｏｒｓ ａｎｄ ｕｓｅ ｔｈｅｒｅｏｆ｝

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
PT910382E (pt) * 1996-04-26 2003-10-31 Genaera Corp Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9727524D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
MXPA01008699A (es) * 1999-02-24 2002-06-21 Uab Research Foundation Derivados de taxano para terapia de cancer dirigida. .
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
KR100881105B1 (ko) * 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
AU2003249000B2 (en) * 2002-08-09 2007-04-05 Astrazeneca Ab Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
KR20050100683A (ko) * 2003-02-13 2005-10-19 아스트라제네카 아베 5-ｆｕ 또는/및 ｃｐｔ-11과 ｚｄ6474의 병용 요법
EP1648465B1 (en) * 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
PL1971338T3 (pl) * 2005-12-22 2011-07-29 Astrazeneca Ab Połączenie ZD6474 i premetreksedu
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy

Also Published As

Publication number Publication date
EP1446124B1 (en) 2006-08-09
NO20042365L (no) 2004-06-07
CN1298328C (zh) 2007-02-07
DE60213845D1 (de) 2006-09-21
WO2003039551A1 (en) 2003-05-15
JP2005511597A (ja) 2005-04-28
US20050043395A1 (en) 2005-02-24
MXPA04004355A (es) 2004-08-11
DE60213845T2 (de) 2007-03-29
CA2464758C (en) 2010-09-28
JP4694127B2 (ja) 2011-06-08
GB0126879D0 (en) 2002-01-02
ATE335488T1 (de) 2006-09-15
CA2464758A1 (en) 2003-05-15
ZA200403455B (en) 2005-08-29
ES2269769T3 (es) 2007-04-01
NO328048B1 (no) 2009-11-16
PT1446124E (pt) 2006-12-29
HK1068546A1 (en) 2005-04-29
IL161744A (en) 2012-01-31
CN1612738A (zh) 2005-05-04
NZ532525A (en) 2006-11-30
KR100959607B1 (ko) 2010-05-27
CY1106259T1 (el) 2011-06-08
AU2002337382B2 (en) 2008-06-12
DK1446124T3 (da) 2006-11-13
KR20050043779A (ko) 2005-05-11
EP1446124A1 (en) 2004-08-18
AR037346A1 (es) 2004-11-03
US20120252827A1 (en) 2012-10-04
BR0213906A (pt) 2004-08-31

Similar Documents

Publication Publication Date Title
IL161744A0 (en) Combination therapy comprising zd6474 and a taxane
GB0111872D0 (en) Therapeutic agents and methods
EP1463438A4 (en) ENDOMURAL THERAPY
PL370563A1 (en) Deuterated substituted pyrazolylbenzylsulfonamides and medicaments comprising said compounds
HUP0600233A3 (en) A combination comprising combretastatin and anticancer agents
GB0119025D0 (en) Compounds and their therapeutic use
GB0108485D0 (en) Combination therapy
GB0101933D0 (en) Therapy
SI1446124T1 (sl) Kombinacijska terapija, ki obsega ZD6474 in taksan
HU0200253D0 (en) Combination therapy
GB2376943B (en) Compounds and their therapeutic use
GB0112237D0 (en) Compounds and their therapeutic use
GB0128122D0 (en) Therapeutic use
GB0123991D0 (en) New therapeutic use
GB0201615D0 (en) Compounds and their therapeutic use
GB0128512D0 (en) Compounds and their therapeutic use
GB0124029D0 (en) Combination therapy
GB0108821D0 (en) Therapy
GB0108817D0 (en) Therapy
GB0108816D0 (en) Therapy
GB0130679D0 (en) Medicaments and novel compounds
GB0130678D0 (en) Medicaments and novel compounds
GB0130785D0 (en) Medicaments and novel compounds
GB0128090D0 (en) Therapeutic use
GB0128128D0 (en) Therapeutic use